Biotech Stock Bubble Debate in 14 Charts

BOSTON ( TheStreet) -- Checking in on the "Biotech Bubble: Yeah or Nay?" debate:

Before we start, let's agree the biotech sector is still having an unbelievable year. IBB Chart IBB data by YCharts

But biotech stocks have underperformed the broader market in the past month. IBB Chart IBB data by YCharts

Momentum-driven biotech stocks -- mostly small- and mid-cap -- have been hit with some serious selling over the past month. These were some of the sector's highest flyers, but not lately. I'm talking about stocks like:

Celldex Therapeutics ( CLDX) : CLDX Chart CLDX data by YCharts

Clovis Oncology ( CLVS): ^NBI Chart ^NBI data by YCharts

and Immunomedics ( IMMU): IMMU Chart IMMU data by YCharts

2013 is shaping up to be a record year for biotech IPOs, but not all of the stellar debuts have staying power.

Bluebird Bio ( BLUE): BLUE Chart BLUE data by YCharts

Alcobra Pharma ( ADHD): ADHD Chart ADHD data by YCharts

Onconova Therapeutics ( ONTX): ONTX Chart ONTX data by YCharts

Stemline Therapeutics ( STML): STML Chart STML data by YCharts

Some biotech IPOs keep moving higher, like...

Receptos ( RCPT) RCPT Chart RCPT data by YCharts

and Ambit BioSciences ( AMBI): AMBI Chart AMBI data by YCharts

Big-cap biotech stocks are still performing strongly. Is there an investor flight to quality companies like Gilead Sciences ( GILD), Amgen ( AMGN), Biogen Idec ( BIIB) and Celgene ( CELG)? GILD Chart GILD data by YCharts

It's definitely NOT been a hard-knock life for orphan drug stocks in 2013: AEGR Chart AEGR data by YCharts

But investors have sent orphans begging in the past month: AEGR Chart AEGR data by YCharts

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks